Humira

RSS

adalimumab

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Humira. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Humira.

For practical information about using Humira, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 21/08/2018

Authorisation details

Product details
Name
Humira
Agency product number
EMEA/H/C/000481
Active substance
adalimumab
International non-proprietary name (INN) or common name
adalimumab
Therapeutic area (MeSH)
  • Spondylitis, Ankylosing
  • Arthritis, Juvenile Rheumatoid
  • Uveitis
  • Colitis, Ulcerative
  • Psoriasis
  • Arthritis, Psoriatic
  • Crohn Disease
  • Arthritis, Rheumatoid
Anatomical therapeutic chemical (ATC) code
L04AB04
Publication details
Marketing-authorisation holder
AbbVie Deutschland GmbH Co. KG
Revision
68
Date of issue of marketing authorisation valid throughout the European Union
07/09/2003
Contact address
Knollstrasse
67061 Ludwigshafen
Germany

Product information

26/07/2018 Humira - EMEA/H/C/000481 - II/0179

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunosuppressants

Therapeutic indication

Please refer to the product information document.

Assessment history

Changes since initial authorisation of medicine

News

How useful was this page?

Add your rating
Average
1 rating
4 ratings
3 ratings
2 ratings
3 ratings